1-4 of 4
David E. Shaw
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3327: Discovery and characterization of the potent, allosteric SHP2 inhibitor GDC-1971 for the treatment of RTK/RAS driven tumors

Bret Williams, Alexander Taylor, Olivia Orozco, Christopher Owen, Elizabeth Kelley, Andre Lescarbeau, Kelley Shortsleeves, Randy Kipp, Vy Nguyen, Erin Brophy, Jeremy Wilbur, Yong Tang, David Lanzetta, Nigel Waters, Sherri Smith, Fabrizio Giordanetto, Paul Maragakis, Jack Greismann, Lindsay Willmore, Eric Therrien, Yang Xiao, Marie Evangelista, Luca Gerosa, Eva Lin, Mark Merchant, Alfonso Arrazate, Emily Chan, Pablo Sáenz-López Larrocha, Stefan Chun, Thomas Hunsaker, Gauri Deshmukh, Christine M. Bowman, David E. Shaw, Mark Murcko, Mahesh Padval, W Patrick Walters, James Watters, Donald A. Bergstrom
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3327.
https://doi.org/10.1158/1538-7445.AM2022-3327
Published: 15 June 2022
View article titled, Abstract 3327: Discovery and characterization of the potent, allosteric SHP2 inhibitor GDC-1971 for the treatment of RTK/RAS driven tumors
Journal Articles

Abstract 78: A strategy for effective targeting of oncogenic BRAF signaling with increased therapeutic index using conformation-selective RAF and MEK inhibitors

Christos Adamopoulos, Tamer A. Ahmed, Maxwell R. Tucker, Peter M. Ung, Min Xiao, Zoi Karoulia, Xuewei Wu, Stuart A. Aaronson, Celina Ang, Vito Rebecca, Avner Schlessinger, Meenhard Herlyn, Qi Wang, David E. Shaw, Poulikos I. Poulikakos
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 78.
https://doi.org/10.1158/1538-7445.AM2021-78
Published: 01 July 2021
View article titled, Abstract 78: A strategy for effective targeting of oncogenic BRAF signaling with increased therapeutic index using conformation-selective RAF and MEK inhibitors
Journal Articles

Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations

Markus A. Seeliger, Pratistha Ranjitkar, Corynn Kasap, Yibing Shan, David E. Shaw, Neil P. Shah, John Kuriyan, Dustin J. Maly
Journal: Cancer Research
Cancer Res (2009) 69 (6): 2384–2392.
https://doi.org/10.1158/0008-5472.CAN-08-3953
Published: 17 March 2009
View article titled, Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations
Open the PDF for Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations in another window
Includes: Supplementary data
Journal Articles

Peptides Derived from the Histidine-Proline Domain of the Histidine-Proline-Rich Glycoprotein Bind to Tropomyosin and Have Antiangiogenic and Antitumor Activities

Fernando Doñate, Jose C. Juarez, Xiaojun Guan, Natalya V. Shipulina, Marian L. Plunkett, Ziva Tel-Tsur, David E. Shaw, William T. Morgan, Andrew P. Mazar
Journal: Cancer Research
Cancer Res (2004) 64 (16): 5812–5817.
https://doi.org/10.1158/0008-5472.CAN-04-0440
Published: 16 August 2004
View article titled, Peptides Derived from the Histidine-Proline Domain of the Histidine-Proline-Rich Glycoprotein Bind to Tropomyosin and Have Antiangiogenic and Antitumor Activities
Open the PDF for Peptides Derived from the Histidine-Proline Domain of the Histidine-Proline-Rich Glycoprotein Bind to Tropomyosin and Have Antiangiogenic and Antitumor Activities in another window